Abstract
Motivation The clinical success of brain-machine interfaces depends on overcoming both biological and material challenges to ensure a long-term stable connection for neural recording and stimulation. Therefore, there is a need to quantify any damage that microelectrodes sustain when they are chronically implanted in the human cortex.
Methods Using scanning electron microscopy (SEM), we imaged 980 microelectrodes from Neuroport arrays chronically implanted in the cortex of three people with tetraplegia for 956-2246 days. We analyzed eleven multi-electrode arrays in total: eight arrays with platinum (Pt) electrode tips and three with sputtered iridium oxide tips (SIROF); one Pt array was left in sterile packaging, serving as a control. The arrays were implanted/explanted across three different clinical sites surgeries (Caltech/UCLA, Caltech/USC and APL/Johns Hopkins) in the anterior intraparietal area, Brodmann’s area 5, motor cortex, and somatosensory cortex.
Human experts rated the electron micrographs of electrodes with respect to five damage metrics: the loss of metal at the electrode tip, the amount of separation between the silicon shank and tip metal, tissue adherence or bio-material to the electrode, damage to the shank insulation and silicone shaft. These metrics were compared to functional outcomes (recording quality, noise, impedance and stimulation ability).
Results Despite higher levels of physical degradation, SIROF electrodes were twice as likely to record neural activity than Pt electrodes (measured by SNR), at the time of explant. Additionally, 1 kHz impedance (measured in vivo prior to explant) significantly correlated with all physical damage metrics, recording, and stimulation performance for SIROF electrodes (but not Pt), suggesting a reliable measurement of in vivo degradation.
We observed a new degradation type, primarily occurring on stimulated electrodes (“pockmarked” vs “cracked”) electrodes; however, tip metalization damage was not significantly higher due to stimulation or amount of charge. Physical damage was centralized to specific regions of an array often with differences between outer and inner electrodes. This is consistent with degradation due to contact with the biologic milieu, influenced by variations in initial manufactured state. From our data, we hypothesize that erosion of the silicon shank often precedes damage to the tip metal, accelerating damage to the electrode / tissue interface.
Conclusions These findings link quantitative measurements, such as impedance, to the physical condition of the microelectrodes and their capacity to record and stimulate. These data could lead to improved manufacturing or novel electrode designs to improve long-term performance of BMIs making them are vitally important as multi-year clinical trials of BMIs are becoming more common.
Competing Interest Statement
NP is a consultant for Boston Scientific and Abbott Laboratories. SK is currently an employee of Blackrock NeuroTech; however, his contribution to this manuscript was in his capacity at the University of Southern California. LR has received grant funding from Blackrock Neurotech for other projects. All other authors have no conflict of interest.
Clinical Trial
NCT01849822, NCT01958086, NCT03161067
Funding Statement
This study was funded by Tianqiao and Chrissy Chen Brain-machine Interface Center Boswell Foundation Craig H. Neilson Foundation NIH/NINDS Grant U01NS098975 NIH/NINDS Grant U01NS123127 NIH/NEI R01EY015545 NIH/NEI UG1EY032039 NIH U01NS098975 DARPA N66001-10-C-4056 DARPA HR001120C0120 NIH/NEI: 1UG3NS107688 DARPA/BTO HAPTIX : N66001-15-C-4017
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All human subject research, experimental design and biomedical devices used for the participant in the Caltech/USC study were approved by the Institutional Review Boards (IRB) of the California Institute of Technology, University of Southern California, and Rancho Los Amigos National Rehabilitation Hospital for collection of this data in a registered clinical trial (NCT01849822). For the participant in the Caltech/UCLA study, all protocols were approved by Institutional Review Boards (IRB) of the California Institute of Technology and University of California Los Angeles (NCT01958086). For the JHU/APL participant, the study was conducted under an FDA Investigational Device Exemption; was approved by the FDA, the Johns Hopkins Institutional Review Board (JH IRB), and the NIWC Human Research Protection Office; and is a registered clinical trial (NCT03161067). All participants gave their written informed consent prior to participation in research-related activities.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵** Senior authors
Data Availability Statement
The data analyzed in this paper will be available upon request.
